Keywords
            Coix lacryma-jobi L. var. 
ma-yuen Stapf - Gramineae - Coix seed - Sodium Dodecyl Sulfate - Skin inflammation - Skin
            dryness
            
 
         
         
               
               
                  
                     CS Coix seed
                     PGE2 prostaglandin E2
                     COX-2 cyclooxygenase 2
                     ICD irritant contact dermatitis
                     SDS sodium dodecyl sulfate
                     GluCer glucosylceramide
                     H&E hematoxylin, and eosin
                     HRP horseradish peroxidase
                     Iba-1 ionized calcium-binding adaptor protein-1
                     IL-1α interleukin-1α
                     CMC-Na sodium carboxymethyl cellulose
                     MRM multiple reaction monitoring
                     SIM selected ion monitoring
                   
                
             
         Introduction
            Coix seed (CS, seeds of Coix lacryma-jobi L. var. ma-yuen Stapf,
               Gramineae) is a traditional Chinese medicine used for invigorating spleen
               function, alleviating arthritis, arresting diarrhea, and treating diabetes [1]. CS contains fatty acids [2], saccharides [3], phenolics [4], and lactams [5].
               Pharmacological research has demonstrated a wide spectrum of biological activities
               of CS, including anti-inflammatory [6]
               [7]
               [8],
               anti-allergic [9], antioxidant [10]
               [11]
               [12], and antitumor activities
               [1]. Several studies using animal models
               have demonstrated that CS exerts anti-inflammatory and anti-allergic effects by
               regulating pro-inflammatory cytokine expression and suppressing cyclooxygenase 2
               (COX-2) and prostaglandin E2 (PGE2) production [13]
               [14].
               CS is widely used as a therapeutic agent for inflammatory skin disorders, such as
               atopic dermatitis [15]
               [16] and acute radiation dermatitis [17]. Surfactant-induced irritant contact
               dermatitis (ICD) is a common skin disorder. However, to the best of our knowledge,
               the efficacy and mechanism of action of CS against surfactant-induced skin disorder
               have not been reported to date.
            Sodium dodecyl sulfate (SDS), a representative anionic surfactant, is widely used
               in
               domestic cleaning, cosmetic, and pharmaceutical products [18]. Prolonged exposure to SDS induces skin
               disorders characterized by skin dryness, scaling, erythema formation, epidermal
               hyperplasia, and inflammatory cell infiltration [19]
               [20]
               [21]. Although the exact mechanism underlying
               SDS-induced skin damage is not fully understood, removal of intercellular lipids or
               alteration of lipid profiles in the stratum corneum [22]
               [23] and the direct toxicity of
               SDS on epidermal cells due to the release of inflammatory mediators, such as
               interleukin-1α (IL-1α) [24]
               [25] and PGE2 [26]
               [27]
               [28], are recognized as the
               major causes of SDS-induced ICD progression. This study aimed to investigate the
               preventive effects of CS on skin inflammation and dryness induced by multiple
               topical applications of SDS on the dorsal skin of hairless mice and elucidate the
               possible mechanism involved.
         Results
            Eight commercially available compounds (Listed in [Table 1]), previously reported as the bioactive components in CS extract
               or its related parts [7]
               [8]
               [29]
               [30]
               [31], were selected to quantify their contents
               in the CS extract via LC MS/MS. The calibration curves for each standard
               were found to be linear with correlation coefficients (R
               
                  2
                  )
               greater than 0.999 for the indicated concentration range (Table 3S, Supporting
               Information). This quantification was performed in triplicate, and the results are
               shown in [Table 1] and [Fig. 1S] (Supporting Information). Among the
               evaluated compounds, the content of p-coumaric acid was the highest, followed
               by coixol, a characteristic CS alkaloid. Naringenin and luteolin were not detected
               in the CS extract. We further analyzed the saccharide and fatty acid contents in the
               primary components of CS extract using HPLC and GC-MS, respectively. Three
               saccharides (glucose, fructose, and sucrose) and four fatty acids (palmitic acid,
               stearic acid, oleic acid, and linoleic acid) were detected, as shown in [Fig. 2S] (Supporting Information). The
               presence of these components was validated by comparison with authentic samples.
            
               
                  
                     
                     
                        Table 1 Contents of the test compounds in Coix seed
                        extract
                     
                  
                     
                     
                        
                        | Compounds | Contents (μg/g)* | RSD (%) | 
                     
                  
                     
                     
                        
                        | Protocatechuic acid | 3.61 | 0.8 | 
                     
                     
                        
                        | 4-Hydroxybenzaldehyde | 3.24 | 0.8 | 
                     
                     
                        
                        | Caffeic acid | 5.78 | 1.6 | 
                     
                     
                        
                        | 
                              p-Coumaric acid | 29.85 | 0.9 | 
                     
                     
                        
                        | 5,7-Dihydroxychromone | 4.49 | 5.8 | 
                     
                     
                        
                        | Naringenin | ND | ND | 
                     
                     
                        
                        | Luteolin | ND | ND | 
                     
                     
                        
                        | Coixol | 9.10 | 4.9 | 
                     
               
               
               
                  *The content of each compound is presented as
                  μg/g of CS extract.; RSD: Relative standard deviation
                  (n=3); ND: not detected, when the signal-to-noise ratio
                  (S/N) was below 3.
                
            
            
            In our preliminary study, we found that daily exposure of mouse dorsal skin to SDS
               caused a gradual decrease in epidermal water content, an indicator of skin dryness,
               and an increase in erythema index, an indicator of skin inflammation. During the
               5-day treatment period, both skin parameters were significantly altered after 5 days
               of SDS exposure ([Fig. 3S], Supporting
               Information); therefore, this time point was selected for evaluating CS extract
               efficacy in this study. The effects of CS against SDS-induced skin dryness and
               inflammation were evaluated by measuring the epidermal water content and skin
               erythema index. Both skin parameters were measured before the start of SDS treatment
               and on the 5th day of the treatment, and the ΔE values are shown
               in [Fig. 1]. CS significantly prevented the
               SDS-induced reduction in epidermal water content in a dose-dependent manner compared
               to that in the SDS-treated group (vehicle group) ([Fig. 1a]). Glucosylceramide (GluCer), a ceramide precursor, was used as
               the positive control and showed an effect similar to that of CS ([Fig. 1a]). In addition, oral administration of
               500 mg/kg CS significantly prevented the increased erythema index
               caused by SDS exposure ([Fig. 1b]). The
               change in the erythema index was not significantly different among the low CS
               (150 mg/kg), GluCer, and vehicle groups ([Fig. 1b]). By day 5, SDS exposure caused an
               increase in the severity of skin scaling ([Fig.
                  2a]), and the score was significantly increased compared to that of
               untreated skin (control group) ([Fig. 2b]).
               Administration of 500 mg/kg CS significantly alleviated the severity
               of skin scaling compared with that in the vehicle group ([Fig. 2b]). A similar effect was observed in
               the GluCer-administered group ([Fig. 2]).
             Fig. 1 Effect of CS on SDS-induced reduction of epidermal water
                  content and elevation of skin erythema index. Epidermal water content and
                  erythema index of the dorsal skin were measured in each mouse before the
                  topical application of SDS on day 5. The data are expressed as Δ
                  epidermal water content (a) and Δ erythema index (b),
                  calculated by subtracting the values obtained before SDS exposure from the
                  values obtained on day 5 after SDS exposure. Bars represent
                  means±standard deviations (n=5 per group);
                  ###
                  p<0.001 vs. control group;
                  *
                  p<0.05,
                   ** 
                  p<0.01,
                   *** 
                  p<0.001
                  vs. vehicle group; Tukey’s test.
                  Fig. 1 Effect of CS on SDS-induced reduction of epidermal water
                  content and elevation of skin erythema index. Epidermal water content and
                  erythema index of the dorsal skin were measured in each mouse before the
                  topical application of SDS on day 5. The data are expressed as Δ
                  epidermal water content (a) and Δ erythema index (b),
                  calculated by subtracting the values obtained before SDS exposure from the
                  values obtained on day 5 after SDS exposure. Bars represent
                  means±standard deviations (n=5 per group);
                  ###
                  p<0.001 vs. control group;
                  *
                  p<0.05,
                   ** 
                  p<0.01,
                   *** 
                  p<0.001
                  vs. vehicle group; Tukey’s test.
            
            
             Fig. 2 Effect of CS on SDS-induced skin scaling. Representative images
                  of the dorsal skin (a) in each group. Photographs were acquired using
                  a digital camera on day 5 after the start of the SDS topical application.
                  Arrows, skin scaling; Scale bars, 10 mm. To evaluate the severity of
                  the SDS-induced skin scaling, the scaling score (b) was derived using
                  a macroscopic scoring system ranging from 0 to 4 (score 0, none; score 1,
                  slight; score 2, moderate; score 3, severe; score 4, very severe) on day 5
                  after the start of SDS topical application. Data points indicate the mode
                  score for each mouse from five investigators (n=5).
                  #
                  p<0.05 vs. vehicle group; post-hoc Steel
                  test.
                  Fig. 2 Effect of CS on SDS-induced skin scaling. Representative images
                  of the dorsal skin (a) in each group. Photographs were acquired using
                  a digital camera on day 5 after the start of the SDS topical application.
                  Arrows, skin scaling; Scale bars, 10 mm. To evaluate the severity of
                  the SDS-induced skin scaling, the scaling score (b) was derived using
                  a macroscopic scoring system ranging from 0 to 4 (score 0, none; score 1,
                  slight; score 2, moderate; score 3, severe; score 4, very severe) on day 5
                  after the start of SDS topical application. Data points indicate the mode
                  score for each mouse from five investigators (n=5).
                  #
                  p<0.05 vs. vehicle group; post-hoc Steel
                  test.
            
            
            To evaluate the effect of CS on epidermal hyperplasia following SDS exposure, we
               stained skin tissue sections with hematoxylin and eosin (H&E) and measured
               epidermal thickness. By day 5, SDS exposure caused approximately 2-fold higher
               epidermal thickening in the vehicle group than in the control group ([Fig. 3a and b]). CS significantly attenuated
               the increased epidermal thickness in a dose-dependent manner ([Fig. 3b]). Infiltration of macrophages and
               neutrophils is reportedly involved in SDS-induced skin inflammatory reactions [21]. To evaluate the effect of CS extract on
               SDS-induced leukocyte infiltration in mouse skin, immunohistochemical staining of
               the macrophage marker ionized calcium-binding adaptor protein-1 (Iba-1) and
               neutrophil marker Ly-6G/Ly-6C was performed. By day 5, SDS exposure resulted
               in macrophage infiltration into the epidermis ([Fig. 3a], Iba–1). The number of Iba-1-positive cells was
               significantly higher in the SDS-treated group than in the control group. CS
               significantly reduced the number of Iba-1-positive cells in a dose-dependent manner
               ([Fig. 3c]). However, no significant
               difference was observed in the number of neutrophils among the groups (data not
               shown).
             Fig. 3 Effect of CS on SDS-induced epidermal hyperplasia and
                  macrophage infiltration in mouse skin. Representative H&E and Iba-1
                  immunohistochemically stained dorsal skin sections (a) on day 5 after
                  the start of SDS topical application. Arrow, Iba-1-positive macrophages;
                  Scale bars, 100 µm. H&E and Iba-1 stained skin
                  sections were used to quantify the epidermal thickness (b) and the
                  density of Iba-1-positive macrophages in the skin (c), respectively.
                  Both quantifications were performed as described in the Materials and
                  Methods section. Data are expressed as means±standard deviations
                  (n=5 per group). ##
                  p<0.01,
                  ###
                  p<0.001 vs. control group;
                  *
                  p<0.05,
                  **
                  p<0.01,
                  ***
                  p<0.001 vs. vehicle
                  group; Tukey’s test.
                  Fig. 3 Effect of CS on SDS-induced epidermal hyperplasia and
                  macrophage infiltration in mouse skin. Representative H&E and Iba-1
                  immunohistochemically stained dorsal skin sections (a) on day 5 after
                  the start of SDS topical application. Arrow, Iba-1-positive macrophages;
                  Scale bars, 100 µm. H&E and Iba-1 stained skin
                  sections were used to quantify the epidermal thickness (b) and the
                  density of Iba-1-positive macrophages in the skin (c), respectively.
                  Both quantifications were performed as described in the Materials and
                  Methods section. Data are expressed as means±standard deviations
                  (n=5 per group). ##
                  p<0.01,
                  ###
                  p<0.001 vs. control group;
                  *
                  p<0.05,
                  **
                  p<0.01,
                  ***
                  p<0.001 vs. vehicle
                  group; Tukey’s test.
            
            
            Irritant-induced skin inflammatory reactions involve increased production of
               inflammatory mediators [32]
               [33]. To elucidate how CS attenuates the
               SDS-induced skin inflammation, we examined the expression of IL-1α and PGE2,
               previously reported to be associated with the SDS-induced inflammatory responses
               [24]
               [26]. The concentrations of IL-1α and PGE2 in the skin tissue in
               the vehicle group were significantly higher than those in the control group. The
               increased levels of IL-1α and PGE2 were significantly attenuated by the
               administration of 500 mg/kg CS ([Fig. 4a, b]). COX-2 regulates the synthesis of PGE2 from arachidonic
               acid. Therefore, we investigated the effect of CS on COX-2 expression using western
               blotting. SDS exposure significantly increased the expression of COX-2, and
               administration of 500 mg/kg CS markedly attenuated this upregulation
               ([Fig. 4c]).
             Fig. 4 Effect of CS on SDS-induced IL-1α, PGE2, and COX-2
                  levels in mouse dorsal skin. Dorsal skin was collected on day 5 after the
                  start of SDS topical application. The production of IL-1α (a)
                  and PGE2 (b) in the dorsal skin was quantified using ELISA. The COX-2
                  protein levels (c) in the dorsal skin were analyzed by western
                  blotting; β-actin was used as the internal standard; Representative
                  immunoblots are shown above the plot in panel C. Data are expressed as
                  means±standard deviations (n=5 per group).
                  #
                  p<0.05 vs. control group;
                  *
                  p<0.05,
                  **
                  p<0.01 vs. vehicle group;
                  Tukey’s test.
                  Fig. 4 Effect of CS on SDS-induced IL-1α, PGE2, and COX-2
                  levels in mouse dorsal skin. Dorsal skin was collected on day 5 after the
                  start of SDS topical application. The production of IL-1α (a)
                  and PGE2 (b) in the dorsal skin was quantified using ELISA. The COX-2
                  protein levels (c) in the dorsal skin were analyzed by western
                  blotting; β-actin was used as the internal standard; Representative
                  immunoblots are shown above the plot in panel C. Data are expressed as
                  means±standard deviations (n=5 per group).
                  #
                  p<0.05 vs. control group;
                  *
                  p<0.05,
                  **
                  p<0.01 vs. vehicle group;
                  Tukey’s test. 
            
            Discussion
            In this study, we investigated the effect of CS on skin inflammation and dryness
               using the SDS-induced ICD model of HR-1 hairless mice and found that CS attenuated
               SDS-induced skin dryness, scaling, erythema, epidermal hyperplasia, and inflammatory
               cell infiltration. Furthermore, CS inhibited the SDS-induced production of
               pro-inflammatory mediators. Our study showed that oral administration of CS can
               protect against surfactant-induced inflammation-mediated skin dryness.
            Enhanced production of pro-inflammatory mediators in the skin is a major
               characteristic of ICD [32]
               [33]. PGE2 is one of the most important
               mediators implicated in ICD [26]
               [27]
               [28].
               It accelerates the blood flow and enhances vascular permeability, leading to
               erythema formation and inflammatory cell infiltration at the site of inflammation
               [34]. Additionally, PGE2 increases
               keratinocyte proliferation and inhibits keratinocyte differentiation in a
               fibroblast-keratinocyte co-culture system [35]. In this study, CS significantly prevented SDS-induced PGE2 production
               ([Fig. 4b]). During PGE2 synthesis, COX-2
               catalyzes the conversion of membrane-released arachidonic acid to PGE2. Our results
               also indicated that SDS-induced COX-2 expression is significantly attenuated by CS
               administration ([Fig. 4c]). Therefore,
               suppressing PGE2 production by inhibiting the COX-2 expression may partially
               ameliorate SDS-induced erythema formation, epidermal hyperplasia, and macrophage
               infiltration by CS ([Fig. 1b] and [3]). Previous studies have indicated that CS
               and its components, such as coixol, caffeic acid, and p-coumaric acid exert
               anti-inflammatory effects by suppressing COX-2 [7]
               [13]
               [36]
               [37].
               These components were predominantly found in the CS extract ([Fig. 1S] and [Table 1]). However, identification of the compounds responsible for the
               protective activity of CS against SDS-induced COX-2-mediated PGE2 production
               requires further investigation. IL-1α, the most abundant cytokine present in
               the skin, is another key mediator involved in the initiation and maintenance of ICD
               [38]. Previous studies have shown that SDS
               induces the overexpression of IL-1α both in vitro and in vivo
               [[24]
               [25]. In response to irritants, IL-1α could be released from
               keratinocytes as an initial step in the inflammatory cascade, subsequently
               stimulating the production and release of more IL-1α and other
               pro-inflammatory cytokines/chemokines from surrounding cells, leading to ICD
               development [38]. Hence, inhibition of
               IL-1α production may prevent the onset of contact dermatitis. Our results
               demonstrated that CS significantly prevented the SDS-induced increase in
               IL-1α production ([Fig. 4a]), which
               prevents the onset of SDS-induced skin inflammation.
            Dried skin with low moisture content is a major hallmark of SDS-induced skin
               disorders [19]
               [22]. CS administration markedly suppressed the SDS-induced reduction in
               epidermal water content ([Fig. 1a]). In
               healthy skin, the proliferation and differentiation of keratinocytes are tightly
               regulated in the epidermis. However, SDS causes uncontrolled proliferation of
               epidermal keratinocytes, leading to the disruption of keratinocyte differentiation,
               resulting in the presence of nucleated keratinocytes in the stratum corneum and
               scaling on the skin surface [39]. These
               incompletely differentiated corneocytes do not have a water-retaining capacity and
               are involved in SDS-induced skin dryness. The oral intake of CS reduces the number
               of nucleated corneocytes in healthy human skin [40]. This finding and our results ([Fig.
                  2]
               [3b]) suggest CS may alleviate
               SDS-induced skin dryness by normalizing the proliferation and differentiation of
               epidermal keratinocytes.
            Removal of intercellular lipids or alteration of lipid profiles in the stratum
               corneum by SDS impairs skin barrier function, which is considered the major cause
               of
               SDS-induced skin dryness [22]
               [23]. Ceramides, the major component of
               intercellular lipids, play a pivotal role in skin barrier integrity and
               moisture-retaining capacity [41]. A previous
               study has demonstrated an inverse relationship between ceramide content and skin
               dryness after SDS exposure [42]. In this
               study, an effect similar to that of CS was observed in the GluCer group ([Fig. 1a]). Linoleic acid, which is abundant in
               the CS extract ([Fig. 2S], b), is a
               ceramide precursor [43], and elevated ceramide
               content in the stratum corneum has been reported in healthy dogs following oral
               administration of linoleic acid [44].
               Therefore, CS-derived linoleic acid may partly contribute to the preventive effects
               of CS against SDS-induced skin dryness by increasing the water-retaining capacity
               of
               the skin.
            In conclusion, oral administration of CS mitigates a series of SDS-induced skin
               disorders, including skin dryness, scaling, erythema, epidermal hyperplasia, and
               macrophage infiltration. The protective effect of CS may be exerted via inhibition
               of the production of IL-1α and COX-2-mediated PGE2.
         Materials and Methods
            Plant materials and extract preparation
            
            The CS plants (Lot# H160722410) were purchased from Koshiro Company Ltd., Osaka,
               Japan, and marker compounds were identified according to the Japanese
               Pharmacopoeia and industry standards of Kracie Pharmaceutical Ltd. A voucher
               specimen (No. 24211) was deposited in the herbarium of Kampo Research
               Laboratories, Kracie Pharmaceutical, Ltd. The CS water extract was prepared
               according to the Guidance published by the Japanese Pharmaceuticals and Medical
               Devices Agency [45]. Briefly, 30 g
               of CS, the daily dosage recommended for adults, was soaked in 600 mL
               distilled water (20 times the amount of CS, v/w) for 1 h in a
               Santo earthenware teapot and concentrated to a final volume of 390 mL
               (13 times the amount of CS, v/w) by boiling. The mixture was filtered
               through gauze and lyophilized to obtain 840 mg of the extract powder
               (yield 2.8%). This extraction was repeated to obtain sufficient extract;
               the extracts were homogenized and stored at –20 °C until further
               use.
            
            Preparation of the standard and sample solutions
            
            The standards, coixol and 5,7-dihydroxychromone, were obtained from
               MedChemExpress Co., Ltd., and ChemFaces Biochemical Co., Ltd., respectively.
               Protocatechuic acid, caffeic acid, p-coumaric acid, and
               4-hydroxybenzaldehyde were purchased from Sigma-Aldrich Co. LLC. Naringenin and
               luteolin were obtained from FUJIFILM Wako Pure Chemical Corporation. All the
               standards were of analytical grade, with purity above 98%. Each standard
               was accurately weighed and dissolved in HPLC-grade methanol (Wako) to prepare
               the respective stock solutions. Calibration standard solutions were prepared by
               appropriate dilutions of the mixed stock solution. The sample solution was
               prepared as described previously [46].
               Briefly, the CS extract (1.0 g) was weighed accurately and dissolved in
               10 mL of ultrapure water (Wako). Next, 10 mL of HPLC-grade
               acetonitrile (Wako) was added, and the mixture was agitated using a shaker
               (Taitec Corporation) for 10 min. A premixed sachet of the QuEChERS
               Extraction salts (Agilent Technologies) was further added to the solution and
               shaken for 10 min. After centrifugation (3000×g,
               10 min), 1 mL of the upper layer solution was transferred into a
               10 mL volumetric flask and diluted with water to obtain the sample
               solution.
            
            Chemical analysis of the CS extract
            
            The standard and sample solutions were analyzed via LC MS/MS on the
               Shimadzu UFLC HPLC system coupled to an LCMS-8030 triple quadrupole mass
               spectrometer. The MS/MS analyses of the standards, except for coixol,
               were performed in the multiple reaction monitoring (MRM) mode; for coixol,
               analysis was in the selected ion monitoring (SIM) mode because no ion pairs were
               detected in the MRM mode. The LC MS/MS conditions and the parameters for
               each analyte are described in the Supporting Information. The saccharides and
               fatty acids in the CS extract were analyzed by HPLC and GC-MS, respectively; the
               details are described in the Supporting Information.
            
            Animals
            
            Seven-week-old male hairless HR-1 mice were purchased from Japan SLC Inc., housed
               at 24±2°C under a 12/12-h light/dark cycle, and
               provided laboratory pellet chow (CE-2, CLEA Japan Inc.) and water ad
                  libitum. The animal experiments in this study were approved (approval
               #190023, August 30, 2019) by the Experimental Animal Care Committee of Kracie
               Pharmaceutical, Ltd. and were performed in accordance with the principles of the
               Basel Declaration and recommendations in the Guidelines for Proper Conduct of
               Animal Experiments.
            
            Treatment
            
            The mice were divided into five groups (n=5) according to their body
               weight. Over 4 weeks, the mice in the first and second groups were orally
               administered 150 and 500 mg/kg per day of CS extract,
               respectively. The dose conversion between animals and humans was performed using
               a previously described calculation [47].
               The third group received pure GluCer (1 mg/kg per day)
               (purity≥99%, Nagara Science) orally and served as a positive
               control [25]. Both CS extract and GluCer
               were dispersed in 1% (w/v) sodium carboxymethyl cellulose
               (CMC-Na) (Wako). The remaining two groups were administered 1% CMC-Na
               alone. Topical application of SDS on the dorsal skin was performed using a
               previously described method [25]. Briefly,
               after 3 weeks of oral administration, medical absorbent cotton (~ca.
               3×4 cm, Kawamoto Corporation) containing 3 mL of
               10% (w/v) SDS (Wako) was placed in contact with the dorsal mouse
               skin for 10 min under isoflurane anesthesia (Wako). SDS exposure was
               performed once daily for 5 consecutive days. CS and GluCer were continuously
               administered 1 h before SDS exposure. As a control for intact skin, one
               group administered 1% CMC-Na alone was not exposed to SDS.
            
            Measurement of skin parameters
            
            Before SDS exposure and on day 5, the skin parameters epidermal water content and
               erythema index were measured using Corneometer® CM825 and
               Mexameter® MX18 (Courage+Khazaka Electronic),
               respectively. All measurements were performed at three sites (upper, middle, and
               lower) along the central line of each SDS-treated skin area under isoflurane
               anesthesia and were repeated five times on the same position. Changes in each
               parameter were calculated using the following formula: index change
               (ΔE)=(value after SDS exposure) – (value before SDS
               exposure).
            
            Evaluation of the severity of skin scaling
            
            The dorsal mouse skin was photographed on day 5 using a digital camera. To
               evaluate the severity of SDS-induced skin scaling using the digital images, a
               macroscopic scoring system ranging from 0 to 4 was developed and evaluated
               blindly by five investigators as follows: score 0, none (absence of scaling on
               the SDS-treated skin area); score 1, slight (appearance of scaling
               on<25% of the area); score 2, moderate (appearance of scaling on
               25–50% of the area); score 3, severe (appearance of scaling on
               50–75% of the area); score 4, very severe (appearance of scaling
               on>75% of the area).
            
            Histological and Immunohistochemical analysis
            
            For histologic analysis, the dorsal skin was fixed in Bouin’s fluid
               (Wako), embedded in paraffin, sectioned (5 μm thickness), and stained
               with H&E. For immunohistochemical analysis, tissues sections (5
               μm thick) were stained with anti-Iba-1 or anti-Ly-6G/Ly-6C
               antibody (Abcam) using the procedure described in our previous study [48]. Images of the stained skin sections
               were captured using a Zeiss Axio Observer Z1 microscope. Epidermal thickness was
               calculated by dividing the area of the epidermis by the length of the basal
               layer, and the densities of Iba-1- or Ly-6G/Ly-6C-positive cells were
               calculated by dividing the number of cells counted by the volume of the counted
               area in five randomly sites of each section using the ZEN2.3 software
               (Zeiss).
            
            ELISA measurements and Western blotting analysis
            
            The levels of IL-1α (R&D Systems) and PGE2 (ENZO) in the skin
               were quantified using ELISA kits according to the manufacturer’s
               protocol. The expression levels of COX-2 protein in the skin were measured by
               western blotting according to the procedure described previously [48]. Immunoreactive bands were visualized
               using an Amersham Imager 680, and band intensities were quantified using
               ImageQuant TL8.2 (GE Healthcare).
            
            Statistical analysis
            
            All statistical analyses were performed using EZR (Version 3.5.2) [49]. Statistical comparisons among multiple
               groups were performed using one-way analysis of variance followed by
               Tukey’s or Kruskal-Wallis test followed by Steel’s post hoc
               tests. Differences were considered significant at p<0.05.
            Supporting Information
            The LC MS/MS conditions and the parameters for each analyte, the procedures
               for HPLC analysis of saccharides and GC-MS analysis of fatty acids in the CS
               extract, and the time-dependent changes in epidermal water content and erythema
               index in both SDS-untreated and treated mouse dorsal skin, are available in the
               Supporting Information.